TAIPEI, Taiwan — August 25, 2026
Senhwa Biosciences announced that it has completed patient enrollment in its Phase 1b expansion trial of pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors carrying BRCA1/2, PALB2 or other homologous recombination deficiency (HRD)-associated alterations. The completion of enrollment marks an important clinical development milestone for the investigational precision oncology therapy and moves the study into data review, reconciliation, database lock and comprehensive statistical analysis. Senhwa expects the Clinical Study Report (CSR) in the first quarter of 2027, with the final analysis intended to guide indication prioritization, biomarker-based patient selection and subsequent development strategies for CX-5461.
CX-5461 Trial Moves Toward Final Data Analysis
The Phase 1b expansion study is evaluating CX-5461 monotherapy in heavily pretreated patients with advanced DNA repair-deficient solid tumors. Enrolled patients include individuals with pancreatic, breast and ovarian cancers, with participants having received a median of six prior lines of therapy, ranging from one to 14. Most patients had previously received multiple standard treatments, including PARP inhibitors, creating a clinically challenging population with significant unmet treatment needs. With enrollment now complete, Senhwa will focus on analyzing the study’s safety, antitumor activity, durability of disease control and overall clinical benefit. Patients who continue to benefit from treatment may enter a protocol-defined extension phase, allowing investigators to collect additional information on long-term safety and sustained disease control.
CX-5461 Targets HRD Tumors Through a Distinct Mechanism
CX-5461 is a first-in-class G-quadruplex stabilizer designed to exploit vulnerabilities in tumors with DNA repair deficiencies through a mechanism distinct from PARP inhibition. The approach is particularly relevant to the evolving HRD treatment landscape, where resistance to PARP inhibitors and disease recurrence remain significant challenges. Preliminary findings presented at the 2026 ASCO Annual Meeting provided an early clinical signal in an exploratory advanced ovarian cancer cohort led by Dr. Amit Oza. Among 16 patients with BRCA mutations, all of whom had previously received PARP inhibitor therapy, CX-5461 achieved a disease control rate of nearly 60%. While these findings remain preliminary and come from a small cohort, they provide clinical rationale for continued investigation of CX-5461 in patients whose disease has progressed following existing DNA damage response therapies.
Advertisement
2027 Data Could Shape Next CX-5461 Development Steps
The forthcoming Phase 1b analysis will be closely watched because it could influence how Senhwa positions CX-5461 across HRD-associated cancers and which biomarkers or patient populations are prioritized for subsequent studies. The company also plans to evaluate potential combination strategies, including combinations with PARP inhibitors, immunotherapies, antibody-drug conjugates and other precision oncology agents. Such strategies could be particularly relevant as oncology development increasingly moves toward biomarker-driven treatment and mechanisms designed to overcome resistance. Senhwa expects the CSR during Q1 2027, providing a key upcoming clinical milestone for CX-5461 and potentially supporting future development, licensing and strategic partnering discussions.
Source:Senhwa Biosciences ,press relese
